Free Trial
NASDAQ:MTVA

MetaVia Q3 2025 Earnings Report

MetaVia logo
$1.00 +0.01 (+0.92%)
As of 01:45 PM Eastern

MetaVia EPS Results

Actual EPS
N/A
Consensus EPS
-$0.26
Beat/Miss
N/A
One Year Ago EPS
N/A

MetaVia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MetaVia Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

MetaVia Earnings Headlines

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate
Nvidia’s slow death march
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
MetaVia assumed with a Buy at H.C. Wainwright
See More MetaVia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email.

About MetaVia

MetaVia (NASDAQ:MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

View MetaVia Profile

More Earnings Resources from MarketBeat